

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | The synthesis of 25-Hydroxycholesterol is catalysed by cholesterol 25-hydroxylase, which uses cholesterol and molecular oxygen as substrates and NADPH as a cofactor. 25-Hydroxycholesterol is a potent biologically active lipid in the innate and adaptive immune system[1]. |
| Concentration | Treated Time | Description | References | |
| HEK293T cells | 1µM | 8h | Inhibited VSV-GFP expression | Immunity. 2013 Jan 24;38(1):92-105 |
| Bovine aortic smooth muscle cells (BASMC) | 1 μg/ml | 24 days | 25-Hydroxycholesterol did not induce nodule formation or calcification in BASMC. | J Clin Invest. 1994 May;93(5):2106-13 |
| Bovine aortic endothelial cells (BAEC) | 1 μg/ml | 24 days | 25-Hydroxycholesterol did not induce nodule formation or calcification in BAEC. | J Clin Invest. 1994 May;93(5):2106-13 |
| Calcifying vascular cells (CVC) | 1 μg/ml | 24 days | 25-Hydroxycholesterol significantly increased the number of mineralized nodules formed by CVC, which were highly calcified. | J Clin Invest. 1994 May;93(5):2106-13 |
| PBMCs (Peripheral Blood Mononuclear Cells) | 0.5 or 1.0 μM | 12 h | To evaluate the inhibitory effect of 25-HC@DDAB on cytokine storm in PBMCs from COVID-19 patients. Results showed that 25-HC@DDAB significantly reduced levels of inflammatory cytokines such as IL-1β. | Nano Today. 2021 Jun;38:101149 |
| BM-derived macrophages (BMDM) | 25 ng/ml | 4 h | To study the effect of 25-HC on lipid body formation, results showed that 25-HC induces lipid body formation. | J Exp Med. 2012 Apr 9;209(4):807-17 |
| Caco2 cells | 0.07 to 16.7 µM | 20 h | Evaluate the inhibitory effect of 25HC and 27HC on HRV infection, results showed both significantly inhibited HRV infection. | Redox Biol. 2018 Oct;19:318-330 |
| MA104 cells | 0.07 to 16.7 µM | 20 h | Evaluate the inhibitory effect of 25HC and 27HC on HRV infection, results showed both significantly inhibited HRV infection. | Redox Biol. 2018 Oct;19:318-330 |
| splenic B220+ cells | 250 nM | 6 days | 25-Hydroxycholesterol suppressed IgA class switch recombination in B cells, particularly when exposed early | Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16764-9 |
| bone marrow-derived macrophages | 500 nM | 24 h | TLR4 activation led to significant increases in 25-hydroxycholesterol and CH25H mRNA and protein levels | Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16764-9 |
| apoE4-expressing microglia | 10 μg/ml | 24 h | apoE4-expressing microglia secrete higher levels of IL-1β after treatment with LPS and 25-HC | J Neuroinflammation. 2020 Jun 17;17(1):192 |
| Primary mouse microglia (PMG) | 5 μg/ml | 24 h | To investigate the effect of 25HC on microglial phagocytic capacity, results showed that 25HC significantly reduced the phagocytic ability of microglia. | J Neuroinflammation. 2025 Feb 25;22(1):50 |
| CEM cells | 5µM | 12h | Inhibited HIV entry | Immunity. 2013 Jan 24;38(1):92-105 |
| HeLa cells | 1µM | 5h | Inhibited Ebola virus replication | Immunity. 2013 Jan 24;38(1):92-105 |
| PBMCs | 1µM | 24h | Inhibited HIV NL4-3 p24 expression | Immunity. 2013 Jan 24;38(1):92-105 |
| J2 BMMs | 1µM | 12h | Reduced VSV replication | Immunity. 2013 Jan 24;38(1):92-105 |
| Bone marrow-derived macrophages (BMDMs) | 1 μM | 24 h | To evaluate the effect of 25-HC on IL-1β production after L. monocytogenes infection. Results showed that Ch25h−/− BMDMs produced more IL-1β, and this effect was inhibited by the addition of 25-HC. | Cell. 2017 Nov 16;171(5):1057-1071. e11 |
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6 mice | Cecal ligation and puncture (CLP)-induced sepsis model | Intravenous injection | 1 μM | Single dose, observed for 96 hours | To evaluate the therapeutic effect of 25-HC@DDAB in a CLP-induced sepsis mouse model. Results showed that 25-HC@DDAB significantly improved survival rate (50%) and reduced inflammation and tissue damage. | Nano Today. 2021 Jun;38:101149 |
| Mouse | 5XFAD transgenic mice | Intraperitoneal injection | 10 mg/kg | Every other day for four weeks | To investigate the effect of 25HC on Alzheimer's disease pathology, results showed that 25HC accelerated amyloid accumulation and exacerbated cognitive and behavioral deficits. | J Neuroinflammation. 2025 Feb 25;22(1):50 |
| C57BL/6 mice | Myocardial ischemia-reperfusion injury model | Intraperitoneal injection | 10 mg/kg | Single dose, 10 minutes before reperfusion | 25-HC significantly reduced myocardial infarct size, improved cardiac function, and inhibited PARP activity. | Int J Biol Sci. 2020 Jan 1;16(2):298-308 |
| NRG-hu mice | Humanized mouse model | Intraperitoneal injection | 50mg/kg | Daily for 14 days | Suppressed HIV replication and rescued T-cell depletion | Immunity. 2013 Jan 24;38(1):92-105 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.48mL 0.50mL 0.25mL |
12.42mL 2.48mL 1.24mL |
24.84mL 4.97mL 2.48mL |
|
| CAS号 | 2140-46-7 |
| 分子式 | C27H46O2 |
| 分子量 | 402.65 |
| SMILES Code | O[C@H](C1)CC[C@@]2(C)C1=CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCCC(O)(C)C |
| MDL No. | MFCD00057815 |
| 别名 | 25-OHC |
| 运输 | 蓝冰 |
| InChI Key | INBGSXNNRGWLJU-ZHHJOTBYSA-N |
| Pubchem ID | 65094 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 4 mg/mL(9.93 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 12 mg/mL(29.8 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1